PMA device
Medtronic Evolut FX System
Medtronic, Inc. · Aortic Valve, Prosthesis, Percutaneously Delivered (NPT, Class III) · First FDA decision Aug 12, 2021, newest Aug 12, 2021Aortic stenosis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
9
Naming "Evolut FX"
MAUDE reports
11,866
Brand "Evolut FX", since 2015
PubMed studies
79
Mentioning "Evolut FX"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Medtronic Evolut FX System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Medtronic Evolut FX SystemPMA supplement
P130021-S094 · Decided Aug 12, 2021 · 90 days after receipt · Normal 180 Day Track
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430RUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430NUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR) for Aortic Regurgitation (AR)National analysisUnder reviewCAG-00430R3Updated Sep 14, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430R2Updated Sep 10, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National determinationOn the books20.32Updated Aug 16, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Evolut FX", any status and sponsor, newest update first.
- Balloon vs. Self Expanding Transcatheter Valve for Degenerated BioprosthesisPivotal-lookingRecruiting
Erasmus Medical CenterAcademic, hospital or other
NCT04843072 · 600 participants (planned) · Start May 1, 2021 · Primary completion Jun 1, 2028
Device: EVOLUT R/PRO/PRO+/FX bioprosthesis; Edwards Sapien S3/Ultra bioprosthesis and 1 more · For: Valve Heart Disease
Sites: Los Angeles, California; Vienna, Austria; Vancouver, Canada · 14 sites in all
- Evolut™ EXPAND TAVR II Pivotal TrialPivotal-lookingActive, not recruiting
Medtronic CardiovascularPublic (MDT)
NCT05149755 · 650 participants (planned) · Start Apr 27, 2022 · Primary completion Sep 2027
Device: Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT) · For: Moderate Aortic Valve Stenosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 94 sites in all
- Comparison of Evolut FX Versus Sapien 3 Ultra Resilia.Pivotal-lookingActive, not recruiting
Christian Juhl TerkelsenAcademic, hospital or other
NCT06470022 · 1,370 participants · Start Aug 9, 2024 · Primary completion Jul 14, 2027
Device: Medtronic Evolut FX; Edwards Sapien 3 Ultra Resilia · For: Aortic Stenosis
Sites: Aarhus, Denmark
6 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Evolut FX", and for the whole product code for context.
This brand
11,866 reports: 3,585 malfunction, 6,889 injury, 1,392 death
Whole product code NPT
77,669 reports: 12,243 malfunction, 57,723 injury, 7,693 death
Newest reports for this brand
- EVOLUT FX DCSMalfunction
9612164-2026-05371 · Received Oct 30, 2026 · Event dated Oct 2, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Particulates; Contamination /Decontamination Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- EVOLUT FX PLUS VALVEMalfunction
Medtronic Mexico S. De R.L. De CV
9617601-2026-06530 · Received Oct 29, 2026 · Event dated Oct 15, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Particulates; Difficult to Open or Remove Packaging Material; Packaging Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- EVOLUT FX VALVEInjury
Medtronic Mexico S. De R.L. De CV
9617601-2026-06541 · Received Oct 29, 2026 · Event dated Oct 29, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Patient Device Interaction Problem
Patient problem as coded: Non specific EKG/ECG Changes
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Medtronic Heart Valves Division
Z-0559-2021 · Started Oct 23, 2020
Reason given: Potential for Transcatheter Aortic Valve (TAV) leaflet damage when performing a post-implant balloon dilatation (PID).
Cause as FDA categorized it: Labeling design · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Medtronic Heart Valves Division
Z-0560-2021 · Started Oct 23, 2020
Reason given: Potential for Transcatheter Aortic Valve (TAV) leaflet damage when performing a post-implant balloon dilatation (PID).
Cause as FDA categorized it: Labeling design · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Medtronic Heart Valves Division
Z-0561-2021 · Started Oct 23, 2020
Reason given: Potential for Transcatheter Aortic Valve (TAV) leaflet damage when performing a post-implant balloon dilatation (PID).
Cause as FDA categorized it: Labeling design · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
1 more recall records with a free account
Published research
The most relevant PubMed records for "Evolut FX"[tiab]. The summary above synthesizes these.
- Editorial: Going from Evolut PRO+ to Evolut FX: A step in the right direction.
Goel SS, Aoun J, Reardon MJ · Cardiovasc Revasc Med · 2024Editorial
- Editorial: TAVR quality improvement with Evolut FX and the role of cusp-overlapping technique.
Grubb KJ, Tully A, Tom S · Cardiovasc Revasc Med · 2023Editorial
- From the Evolut Pro to the Evolut FX self-expanding transcatheter aortic valve replacement systems: current status and future perspectives.
Panagides V, Mesnier J, Nuche J, et al. · Expert Rev Med Devices · 2022Review
- A TAV-in-TAV-in-SAV Lifetime Management.
Bianchini E, Linnane M, Sgreva S, et al. · JACC Case Rep · 2026Case Reports
- Use and performance of the evolut FX transcatheter aortic valve system.
Bajwa T, Attizzani GF, Gada H, et al. · Cardiovasc Revasc Med · 2024Multicenter Study, Research Support, Non-U.S. Gov't
- Nordic consensus document on Evolut FX+ transcatheter aortic valve implantation: optimizing index implantation and longer-term outcomes.
Khokhar AA, Savontaus M, Al-Ani A, et al. · Front Cardiovasc Med · 2025Review
- Valve Performance Between Latest-Generation Balloon-Expandable and Self-Expandable Transcatheter Heart Valves in a Small Aortic Annulus.
Hioki H, Yamamoto M, Shirai S, et al. · JACC Cardiovasc Interv · 2024Comparative Study, Research Support, Non-U.S. Gov't
- Alpha-Gal Syndrome and Aortic Valve Replacement.
Sami N, Ravishankar B, Worku B, et al. · JACC Case Rep · 2025Case Reports
- Differences in Coronary Alignment Between Evolut FX and Navitor Valves.
Hirofumi H, Masanori Y, Tomoki O, et al. · Catheter Cardiovasc Interv · 2025Comparative Study, Research Support, Non-U.S. Gov't
- Impella 5.5 Placement Across Evolut FX Transcatheter Aortic Valve: Balloon-Assisted Procedure.
Narita M, Nishijima S, Katagiri Y, et al. · Ann Thorac Surg Short Rep · 2024
- Early experience with the Evolut FX self-expanding valve vs. Evolut PRO+ for patients with aortic stenosis undergoing TAVR.
Merdler I, Case B, Bhogal S, et al. · Cardiovasc Revasc Med · 2023
- First-in-Human Multicenter Experience of the Newest Generation Supra-Annular Self-Expanding Evolut FX TAVR System.
Zaid S, Attizzani GF, Krishnamoorthy P, et al. · JACC Cardiovasc Interv · 2023Multicenter Study, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code NPT.
- Sapien 3 Transcatheter Heart Valve and AccessoriesEdwards Lifesciences, LLC · PMA 2025
- Medtronic CoreValve Evolut R SystemMedtronic, Inc. · PMA 2022
- Edwards SAPIEN XT Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2020
- Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2026
- Medtronic CoreValve SystemMedtronic, Inc. · PMA 2023
- Edwards Sapien Transcatheter Heart Valve and Transfemoral and Transapical AccessoriesEdwards Lifesciences, LLC · PMA 2013
- Navitor Transcatheter Aortic Valve Implantation SystemAbbott Medical · PMA 2026
- Trilogy Transcatheter Heart Valve SystemJenaValve Technology, Inc. · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.